Post-transplant Lymphoproliferative Disorder Successfully Treated with Pola-R-CHP and Achieved Long-term Remission.

Masahiro Shino, Akira Honda, Hideaki Mizuno, Arika Shimura, Hiroaki Maki, Aya Shinozaki-Ushiku, Mineo Kurokawa

Abstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masahiro ShinoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Akira HondaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Hideaki MizunoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Arika ShimuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Hiroaki MakiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Aya Shinozaki-UshikuDepartment of Pathology, The University of Tokyo Hospital, Japan.

Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening condition for organ transplantations. There are no established treatments for PTLD, and it is associated with a poor prognosis. Patients with PTLD treated with Pola-R-CHP have rarely been reported, and long-term remission results are unknown. This is the first report of previously untreated PTLD treated with a Pola-R-CHP regimen that achieved long-term remission. Pola-R-CHP may be a promising treatment option for patients with PTLD, especially monomorphic diffuse large B-cell lymphoma, and those with an increased International Prognostic Index score.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsKidney TransplantationLymphoproliferative DisordersPostoperative ComplicationsCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedRemission InductionRituximabTime FactorsTreatment OutcomeVincristineCyclophosphamideDoxorubicinRituximabVincristinePola-R-CHPpost-transplant lymphoproliferative disorder

Identifiers

PMID40707217

DOI10.2169/internalmedicine.5387-25

PMCPMC12979672

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.